Le Lézard
Classified in: Science and technology, Business
Subjects: EARNINGS, Conference, Webcast, Advisory

NetApp Hosts Fourth Quarter and Fiscal Year 2024 Financial Results Webcast


After market close on Thursday, May 30, 2024, NetApp (NASDAQ: NTAP) will announce financial results for the fourth quarter and fiscal year 2024 which ended April 26, 2024.

NetApp executive management will host a conference call at 2:30 p.m. Pacific Time to discuss these results and provide their perspective on market dynamics.

How to Participate

The live Webcast call can be accessed at investors.netapp.com. Please allow at least 15 minutes prior to the start of the Webcast to log in. An audio replay Webcast will also be available after 4:30 p.m. Pacific Time.

NetApp Future Targeted Release Dates

Q1 FY 2025 results target date: August 28, 2024
Q2 FY 2025 results target date: November 26, 2024
Q3 FY 2025 results target date: February 27, 2025
Q4 FY 2025 results target date: May 29, 2025

About NetApp

NetApp is the intelligent data infrastructure company combining unified data storage, integrated data services, and CloudOps solutions to turn a world of disruption into opportunity for every customer. NetApp creates silo-free infrastructure, then harnesses observability and AI, to enable the best data management. As the only enterprise-grade storage service natively embedded in the world's biggest clouds, our data storage delivers seamless flexibility and our data services create a data advantage through superior cyber-resilience, governance, and applications agility. Our CloudOps solutions provide continuous optimization of performance and efficiency through observability and AI. No matter the data type, workload, or environment, transform your data infrastructure to realize your business possibilities with NetApp.

Learn more at www.netapp.com or follow us on X, LinkedIn, Facebook, and Instagram.

NETAPP, the NETAPP logo, and the marks listed at http://www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.


These press releases may also interest you

at 06:02
Weekly Recap: 11 Press Releases You Might Have Missed
With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major...

at 06:00
Amplify10 Unveils Groundbreaking AI-Powered Sales Execution Platform, Revolutionizing Enterprise Sales Performance
Amplify10, the trailblazer in SaaS AI-Powered Sales Execution solutions, proudly announces its official launch today, aimed at reshaping the landscape of sales performance for enterprises worldwide. The early-stage company, formerly known as...

at 06:00
Quhuo Announces Changes to Board of Directors
Quhuo Limited ("Quhuo" or the "Company") , a leading gig economy platform focusing on local life services in China, today announced that Ms. Chenxi Zhao has resigned from her position as a member of the board of directors (the "Board"), effective on...

at 05:50
NADclinic and Bontac Bio-Engineering (Shenzhen) Co., Ltd Announce Strategic Partnership to Evolve the Future of Global Wellness Through the Power of NAD+
NADclinic Group and Bontac Bio-Engineering (Shenzhen) Co., Ltd have officially entered into a dynamic strategic partnership to collaboratively focus on the future of global health and wellness. Synergistically leveraging their collective expertise...

at 05:45
China Duty Free Group outlines growth strategy at TFWA Asia Pacific Conference
A report from China.org.cn:  China Duty Free Group (CDFG), the world's leading travel retail operator, outlined its strategy for continued growth at the recently concluded TFWA Asia Pacific Exhibition & Conference held in Singapore from May 12 to...

at 05:35
Drug Farm Announces IND Clearance by U.S. FDA Enabling Phase 1b Initiation for ALPK1 Selective Kinase Inhibitor, DF-003 in ROSAH Syndrome Patients
Drug Farm announced today the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of DF-003, a first-in-class, oral, potent, highly selective alpha-kinase 1 (ALPK1) inhibitor for clinical evaluation in...

More news about Science and technology...


News published on and distributed by: